Joyce Struna, PA
Physician Assistant · Cheyenne, WYNPI 1003068263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Among physician assistant clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$651
- AbbVie$462
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$197
- Johnson & Johnson$179
- Lilly USA, LLC$161
- Amgen$153
- plus $767 from 17 others
What the payments were for
- Food & beverage$2,570100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $651 |
| AbbVie | 30 | $462 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $197 |
| Johnson & Johnson | 10 | $179 |
| Lilly USA, LLC | 10 | $161 |
| Amgen | 9 | $153 |
| Exact Sciences | 2 | $145 |
| Bayer | 5 | $91 |
| Boehringer Ingelheim | 5 | $90 |
| AstraZeneca | 6 | $87 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Pfizer | 3 | $50 |
| GSK | 3 | $46 |
| Corcept Therapeutics | 2 | $32 |
| Organon | 2 | $26 |
| Inari Medical, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,570 in reported general payments places this provider in the 90th percentile of 203 physician assistant providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 94 | $79,433 |
| OzempicSemaglutide | 62 | $73,485 |
| EliquisApixaban | 69 | $66,112 |
| MounjaroTirzepatide | 20 | $23,030 |
| XareltoRivaroxaban | 33 | $23,020 |
| CreonLipase/Protease/Amylase | 14 | $19,666 |
| RybelsusSemaglutide | 17 | $19,163 |
| Repatha SureclickEvolocumab | 11 | $14,738 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,310 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $10,054 |
| Spiriva HandihalerTiotropium Bromide | 17 | $9,486 |
| KerendiaFinerenone | 12 | $8,811 |
| JanuviaSitagliptin Phosphate | 11 | $7,194 |
| Atomoxetine Hcl | 11 | $6,068 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $5,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $651 | $92,64879 claims |
| Boehringer IngelheimJardiance | $90 | $79,43394 claims |
| PfizerEliquis | $50 | $66,11269 claims |
| Lilly USA, LLCMounjaro | $161 | $23,03020 claims |
| Johnson & JohnsonXarelto | $179 | $23,02033 claims |
| AbbVieCreon, Synthroid | $462 | $21,42636 claims |
| GSKTrelegy Ellipta | $46 | $14,31014 claims |
| BayerKerendia | $91 | $8,81112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 203 physician assistant providers in Wyoming.
Other physician assistant in Cheyenne
- Alison WatkinsCheyenne$3K
- Ellen KingdomCheyenne$3K
- Kevin CurtisCheyenne$3K
- Caitlyn McCueCheyenne$3K
- May Katharine LehmanCheyenne$2K
- Alissa AylwardCheyenne$1K
- Shannon LambertCheyenne$1K
- Karen GaffordCheyenne$1K
- Amanda DiefenderferCheyenne$1K
- Tanja SloanSheridan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.